Clinical trial

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

NCT00542191

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Definitive Surgery Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Radiotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2007-07-01

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

Doxorubicin / Cyclophosphamide / Paclitaxel / CarboplatinDRUG

Definitive SurgeryPROCEDURE

RadiotherapyRADIATION

Sponsors & collaborators

Leo W. Jenkins Cancer Centerlead sponsor

Mapped research locations

GreenvilleNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00542191 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.